Phase 2 N=24 Aerosol Inhalation Treatment for Dyspnea
Healthy · Dyspnea
Primary: Subject Rating of Breathing Discomfort (Dyspnea) — 20; 20; 16; 17 units on a scale — p=0.99
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=247 Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
Lung Cancer
Primary: Modified Medical Research Council Dyspnea Scale (mMRCDS) — 1.88; 1.55 units on a scale — p=0.038
Phase 3 N=246 The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Total Total Transient Dyspnea Index (TDI) Score After 6 Weeks of Treatment QVA149 Compared to Placebo — 7.34; 7.33; 0.98; -0.38 Units on a scale
N/A N=16 The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing
Chronic Obstructive Pulmonary Disease
Primary: Intensity of Breathlessness — 80.8; 77.9 units on a scale
Phase 2 N=24 Aerosol Inhalation Treatment for Dyspnea - Patients
Dyspnea
Primary: Change in Subject Rating of Breathing Discomfort (Dyspnea) Before and After Treatment. — -1.86; -0.61; -0.15 units on a scale — p=0.35
N/A N=25 Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients
COPD · Dyspnea
Primary: Average Distance During Modified 6 Minute Walk Test — 128.0; 129.9; 137.5; 121.3 meters — p=0.02
N/A N=60 Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI
Dyspnea
Primary: Number of Participants With Transient Dyspnea. — 23 Participants
Phase 2 N=30 High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer
Advanced Cancers
Primary: Number of Participants Completing Study Intervention — 7; 10; 3; 5 Participants
Phase 4 N=106 Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Intensity of Breathlessness Measured Using the Modified Borg Scale at the End of the 3 Minute (Min) Constant Speed Shuttle Test After 6 Weeks of…
N/A N=14 Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Intensity of Breathlessness — 77; 83 units on a scale — p=.0004
N/A N=16 Effect of Inhaled Fentanyl on Dyspnea and Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Dyspnea Intensity Measured by the 10-point Borg Scale During Cycle Exercise — 2.6; 2.0 units on a scale
Phase 2 N=19 High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients
Cancer
Primary: Change in Dyspnea Numeric Score Between 0 and 10 Minutes — -1.8; -1.8; -0.6; -0.5 score on a scale
Phase 2 N=41 Dexamethasone Dyspnea Study
Advanced Cancers · Hematologic Disorder · Solid Tumors
Primary: Number of Participants Who Completed the Dyspnea Numeric Rating Scale — 18; 17 Participants
Phase 4 N=418 Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Internal Consistency (IC) of the Shortness of Breath With Daily Activities (SOBDA) Questionnaire in Participants With Chronic Obstructive Pulmonary Disease (COPD)…
Phase 3 N=34 Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea
Advanced Cancers
Primary: Modified Dyspnea Borg Scale (Dyspnea Intensity) — -1.4; -0.5 score on a scale
Phase 3 N=432 Buspirone in Reducing Shortness of Breath in Patients With Cancer
Dyspnea · Pulmonary Complications · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Dyspnea as Measured by Oxygen Cost Diagram (OCD) — 8.98; 9.32 units on a scale — p=0.080
Phase 3 N=17 Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD
COPD
Primary: Exertional Dyspnea Intensity at Isotime Exercise. — 3.9; 3.4 units on a scale — p=0.090
N/A N=92 Respiratory Dysregulation and Breathing Training in Anxious Outpatients
Anxiety
Primary: Episodic Anxiety Scale — 8.1; 9.0; 14.3 units on a scale
N/A N=30 In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency
Pulmonary Disease, Chronic Obstructive · Airflow Obstruction, Chronic · Chronic Obstructive Airway Disease
Primary: Activity Endurance Time — 7.24; 13.38 minutes — p=<0.05
N/A N=22 Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive · Airflow Obstruction, Chronic · Chronic Obstructive Airway Disease
Primary: Device Tidal Volume — 180 mL
N/A N=27 Inspiratory Muscle Rehabilitation in Children With Obesity
Pediatric Obesity
Primary: Number of Participants Who Complete Study Visit 3 — 12; 13 Participants
N/A N=26 Clinical Efficacy in Relief of Dyspnea by HVNI: Evaluation of New Cannulae Designs
Dyspnea · Hypercapnia · Respiratory Insufficiency
Primary: Patient Vital Signs -- Rated Perceived Dyspnea (RPD) — 3; 2.5; 2.5 units on a scale
Phase 2 N=35 Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea
Advanced Cancers
Primary: Dyspnea Numeric Rating Scale — -2.0; -1.7; -2.3; -2.5 score on a scale
N/A N=15 Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Exercise Duration for Constant Work Rate Exercise Tests Under 4 Test Conditions — 6.3; 17.5; 11.4; 5.6 minutes — p=<0.05
Phase 2 N=360 Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study
Acute Heart Failure
Primary: Change in Cystatin C — .12; .11; .07 mg/L
N/A N=9 BRAIN, Symptoms, and Physical Activity in COPD
COPD · Chronic Musculoskeletal Pain
Primary: Cortical Thickness — 2.2 mm
N/A N=25 Respiratory Strength Training in Cardiac Surgical Patients
Cardiovascular Diseases · Thoracic Diseases · Surgery
Primary: Adherence to Respiratory Strength Training — 35750 Repetitions
N/A N=146 Expiratory Muscle Training in Stroke
Stroke · Mastication Disorder · Temporomandibular Disorders
Primary: Change in Masticatory Performance — 24; 13; 25; 16 percentage of masticated peanuts